Special Issue "Current Updates on Theragnostic Strategies for Intervention of Brain Diseases and Pathology"

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuropharmacology and Neuropathology".

Deadline for manuscript submissions: 7 December 2023 | Viewed by 1454

Special Issue Editor

Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University Campus of the University of North Carolina, Elizabeth City, NC 27909, USA
Interests: cancer apoptosis; ceramide; glioma; biomarker discovery, theranostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Brain is the final frontier for biomedical researchers, as the function of the brain has yet to be demystified; we need to have constant updates in the field of cognitive neurosciences and theragnostic interventions to maintain neural homeostatic mechanisms. We are inviting manuscripts related to all aspects of brain sciences and pathology, including advances in brain cancers, Alzheimer’s disease, Parkinsonism, ALS and FALS, multiple sclerosis, stroke and cerebrovascular accidents, including etiology as well as newer diagnostic, prognostic and therapeutic strategies for effective interventions. This Special Issue of Brain Sciences will charge no publication fees for up to ten accepted peer-reviewed manuscripts.

Prof. Dr. Hirendra Nath Banerjee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain cancers
  • theragnostic strategies
  • cognitive neurosciences

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Enhanced Targeted Delivery of Minocycline via Transferrin Conjugated Albumin Nanoparticle Improves Neuroprotection in a Blast Traumatic Brain Injury Model
Brain Sci. 2023, 13(3), 402; https://doi.org/10.3390/brainsci13030402 - 25 Feb 2023
Viewed by 1164
Abstract
Traumatic brain injury (TBI) is a major source of death and disability worldwide as a result of motor vehicle accidents, falls, attacks and bomb explosions. Currently, there are no FDA-approved drugs to treat TBI patients predominantly because of a lack of appropriate methods [...] Read more.
Traumatic brain injury (TBI) is a major source of death and disability worldwide as a result of motor vehicle accidents, falls, attacks and bomb explosions. Currently, there are no FDA-approved drugs to treat TBI patients predominantly because of a lack of appropriate methods to deliver drugs to the brain for therapeutic effect. Existing clinical and pre-clinical studies have shown that minocycline’s neuroprotective effects either through high plasma protein binding or an increased dosage requirement have resulted in neurotoxicity. In this study, we focus on the formulation, characterization, in vivo biodistribution, behavioral improvements, neuroprotective effect and toxicity of transferrin receptor-targeted (tf) conjugated minocycline loaded albumin nanoparticles in a blast-induced TBI model. A novel tf conjugated minocycline encapsulated albumin nanoparticle was developed, characterized and quantified using a validated HPLC method as well as other various analytical methods. The results of the nanoformulation showed small, narrow hydrodynamic size distributions, with high entrapment, loading efficiencies and sustained release profiles. Furthermore, the nanoparticle administered at minimal doses in a rat model of blast TBI was able to cross the blood–brain barrier, enhanced nanoparticle accumulation in the brain, improved behavioral outcomes, neuroprotection, and reduced toxicity compared to free minocycline. Hence, tf conjugated minocycline loaded nanoparticle elicits a neuroprotective effect and can thus offer a potential therapeutic effect. Full article
Show Figures

Figure 1

Back to TopTop